Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMedOpen access

MARCH1 Deletion Attenuates HFpEF by Promoting Adipose Beiging.

Zhu Y., Fan J., Tang L., Zhou Y., Jiang K., Tan D.

Animal Study on Cardiovascular Disease, published in Compr Physiol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Compr Physiol (2026)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
41986908
PMCID
PMC13083538
DOI
10.1002/cph4.70141

Abstract (original English)

Membrane-associated RING-CH1 (MARCH1) is a critical membrane-bound RING domain E3 ubiquitin ligase that primarily regulates immune cell development, immune responses, antigen presentation modulation, and metabolic functions. Its role in the pathogenesis of heart failure with preserved ejection fraction (HFpEF) remains elusive. This study aimed to investigate the function of MARCH1 in HFpEF. Multi-hit (high fat/sugar diet together with deoxycorticosterone acetate and angiotensin II injection) HFpEF mouse model was established in C57BL/6 wild-type mice and MARCH1 KO mice. Non-HFpEF control mice received standard diet. Comprehensive evaluation was carried out through echocardiography, histological and biochemical studies. White adipose tissue (WAT) beiging was analyzed in isolated stromal vascular fraction cells. The relevant molecular mechanisms were determined through RNA sequencing and co-immunoprecipitation assay. Cardiometabolic dysregulation with hypertension and obesity was observed in WT HFpEF mice. Significantly reduced running distance and running time were found in HFpEF mice compared to the WT control mice (both p < 0.05). Histologic and echocardiographic examinations also visualized cardiac fibrosis, left ventricular hypertrophy, and diastolic dysfunction in HFpEF mice. MARCH1 expression was significantly upregulated in the WAT of HFpEF mice. MARCH1 deficiency allevia

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research